Phase 1 (173 companies)
Companies with at least one active program at Phase 1.
| Ticker | Company | Therapeutic areas | Phase 1 programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ABSI | Absci | DermatologyGI/Hepatology+1 | 3 | Phase 1 | $1.31B | 6 |
| ACIU | AC Immune | Neurology Rare | 5 | Phase 3 | $210M | 11 |
| ACRS | Aclaris Therapeutics | DermatologyGI/Hepatology+1 Rare | 3 | Phase 2 | $536M | 7 |
| ACRV | Acrivon Therapeutics | GI/HepatologyOncology Rare | 3 | Phase 2 | $61.4M | 9 |
| ACTU | Actuate Therapeutics | Oncology | 2 | Phase 2 | $15.2M | 4 |
| ABOS | Acumen Pharmaceuticals | Neurology | 1 | Phase 2 | $16.6M | 4 |
| ADAG | Adagene | Oncology | 4 | Phase 2 | $99.4M | 10 |
| ACET | Adicet Bio | ImmunologyNeurology+2 Rare | 7 | Phase 1 | $26.0M | 8 |
| AGIO | Agios Pharmaceuticals | HematologyMetabolic Rare | 2 | Approved | $1.79B | 7 |
| AGMB | Agomab Therapeutics | ImmunologyRespiratory Rare | 1 | Phase 2 | $292M | 4 |
| AKBA | Akebia Therapeutics | HematologyOphthalmology+2 Rare | 1 | Approved | $111M | 10 |
| AKTS | Aktis Oncology | Oncology | 10 | Phase 1 | $910M | 10 |
| ALDX | Aldeyra Therapeutics | DermatologyOncology+1 | 1 | NDA Submitted | $41.9M | 5 |
| ALLO | Allogene Therapeutics | ImmunologyOncology Rare | 5 | Phase 2 | $256M | 10 |
| DRTS | Alpha Tau Medical | Oncology | 1 | Phase 2 | $1.12B | 6 |
| ALMS | Alumis | DermatologyImmunology+1 | 1 | Phase 3 | $628M | 5 |
| AMLX | Amylyx Pharmaceuticals | MetabolicNeurology Rare | 1 | Phase 3 | $3.54B | 5 |
| ANTX | AN2 Therapeutics | HematologyInfectious Disease+1 Rare | 3 | Phase 2 | $161M | 6 |
| ANAB | AnaptysBio | DermatologyGI/Hepatology+2 Rare | 3 | Approved | $1.36B | 9 |
| ANIX | Anixa Biosciences | Oncology | 2 | Phase 1 | $92.8M | 3 |
| ANNX | Annexon | HematologyNeurology+2 Rare | 2 | Phase 3 | $662M | 6 |
| APGE | Apogee Therapeutics | DermatologyGI/Hepatology+1 Rare | 5 | Phase 2 | — | 9 |
| APVO | Aptevo Therapeutics | Oncology | 2 | Phase 1 | $1.6M | 8 |
| RCUS | Arcus Biosciences | DermatologyImmunology+1 | 3 | Phase 3 | $2.36B | 8 |
| AVBP | ArriVent BioPharma | Oncology | 4 | Phase 3 | $553M | 7 |
| ARTV | Artiva Biotherapeutics | Oncology | 1 | Phase 1 | $191M | 6 |
| ARVN | Arvinas | NeurologyOncology Rare | 7 | Approved | $447M | 10 |
| AUTL | Autolus Therapeutics | HematologyImmunology+3 Rare | 9 | Approved | $290M | 12 |
| BEAM | Beam Therapeutics | HematologyMetabolic+1 Rare | 4 | Phase 2 | $2.14B | 6 |
| BCAX | Bicara Therapeutics | Oncology | 3 | Phase 2 | $637M | 4 |
| BCYC | Bicycle Therapeutics | Oncology | 1 | Phase 2 | $224M | 4 |
| BCRX | Biocryst Pharmaceuticals | DermatologyImmunology+1 Rare | 1 | Approved | $1.93B | 4 |
| BMEA | Biomea Fusion | MetabolicOncology | 2 | Phase 2 | $35.5M | 4 |
| BDTX | Black Diamond Therapeutics | Oncology | 1 | Phase 2 | $82.8M | 4 |
| BCTX | BriaCell Therapeutics | Oncology | 1 | Phase 3 | $30.7M | 8 |
| BBOT | BridgeBio Oncology Therapeutics | Oncology | 6 | Phase 1 | $156M | 6 |
| CCCC | C4 Therapeutics | Oncology | 1 | Phase 2 | $332M | 2 |
| CABA | Cabaletta Bio | DermatologyImmunology+2 Rare | 8 | Phase 2 | $220M | 8 |
| CAMP | Camp4 Therapeutics | — | 1 | Phase 1 | $251M | 1 |
| CADL | Candel Therapeutics | Oncology | 1 | Phase 3 | $424M | 4 |
| CAPR | Capricor Therapeutics | Infectious DiseaseNeurology Rare | 1 | NDA Submitted | $489M | 2 |
| RNAC | Cartesian Therapeutics | ImmunologyNeurology+1 Rare | 2 | Phase 3 | $187M | 4 |
| CLDX | Celldex Therapeutics | DermatologyImmunology+1 | 1 | Phase 3 | $2.20B | 6 |
| CLRB | Cellectar Biosciences | Oncology | 2 | Phase 2 | $9.2M | 7 |
| IPSC | Century Therapeutics | ImmunologyMetabolic+1 Rare | 4 | Phase 1 | $249M | 9 |
| CLYM | Climb Bio | HematologyImmunology+1 Rare | 5 | Phase 2 | $574M | 8 |
| COGT | Cogent Biosciences | HematologyOncology Rare | 2 | NDA Submitted | $4.85B | 7 |
| CHRS | Coherus Oncology | Oncology | 2 | Approved | $74.0M | 5 |
| CMPX | Compass Therapeutics | Oncology | 13 | Phase 2 | $109M | 15 |
| CGEN | Compugen | Oncology | 2 | Phase 3 | $191M | 7 |
| CTNM | Contineum Therapeutics | NeurologyRespiratory Rare | 1 | Phase 2 | $375M | 4 |
| CRVS | Corvus Pharmaceuticals | DermatologyOncology+1 Rare | 1 | Phase 3 | $858M | 7 |
| COYA | Coya Therapeutics | Neurology Rare | 1 | Phase 2 | $70.8M | 6 |
| CBIO | Crescent Biopharma | Oncology | 9 | Phase 2 | $507M | 10 |
| CRNX | Crinetics Pharmaceuticals | MetabolicOncology Rare | 2 | Approved | — | 6 |
| CUE | Cue Biopharma | ImmunologyOncology | 3 | Phase 2 | $23.7M | 6 |
| CGEM | Cullinan Therapeutics | HematologyImmunology+2 Rare | 6 | NDA Submitted | $602M | 10 |
| CTMX | CytomX Therapeutics | Oncology | 6 | Phase 1 | $423M | 7 |
| DBVT | DBV Technologies | Immunology | 1 | NDA Submitted | $3.14B | 2 |
| IRON | Disc Medicine | GI/HepatologyHematology+2 Rare | 3 | Phase 3 | $3.49B | 9 |
| EIKN | Eikon Therapeutics | Oncology | 10 | Phase 2 | $279M | 13 |
| ELDN | Eledon Pharmaceuticals | ImmunologyMetabolic+1 Rare | 1 | Phase 2 | $167M | 3 |
| ELTX | Elicio Therapeutics | Oncology | 2 | Phase 2 | $40.5M | 6 |
| ELOX | Eloxx Pharmaceuticals | DermatologyRenal Rare | 3 | Phase 2 | $48.0M | 4 |
| ENTA | Enanta Pharmaceuticals | DermatologyImmunology+2 | 2 | Approved | $253M | 8 |
| ELVN | Enliven Therapeutics | Oncology | 1 | Phase 1 | $3.45B | 1 |
| ERAS | Erasca | Oncology | 2 | Phase 1 | $4.87B | 5 |
| ETON | Eton Pharmaceuticals | GI/HepatologyInfectious Disease+3 Rare | 1 | Approved | $1.84B | 17 |
| EXEL | Exelixis | CardiovascularOncology | 7 | Approved | $16.7B | 23 |
| FATE | Fate Therapeutics | ImmunologyOncology+1 Rare | 6 | Phase 2 | $124M | 10 |
| FBRX | Forte Biosciences | DermatologyGI/Hepatology | 2 | Phase 2 | — | 3 |
| FBIO | Fortress Biotech | DermatologyHematology+4 Rare | 3 | Approved | $61.4M | 16 |
| GANX | Gain Therapeutics | MetabolicNeurology Rare | 1 | Phase 1 | $52.5M | 5 |
| GNLX | Genelux | Oncology | 1 | Phase 3 | $96.1M | 3 |
| GHRS | GH Research | NeurologyWomen's Health | 1 | Phase 2 | $1.25B | 4 |
| HRMY | Harmony Biosciences | MetabolicNeurology Rare | 2 | Approved | $1.94B | 17 |
| IDYA | IDEAYA Biosciences | Oncology | 12 | NDA Submitted | $2.65B | 15 |
| IMTX | Immatics | Oncology | 7 | Phase 3 | $958M | 8 |
| IMMX | Immix Biopharma | Hematology Rare | 1 | Phase 1 | $603M | 1 |
| IMRX | Immuneering | Oncology | 4 | Phase 3 | $224M | 5 |
| IMUX | Immunic | GI/HepatologyNeurology | 1 | Phase 3 | $116M | 4 |
| IBRX | ImmunityBio | Infectious DiseaseOncology | 4 | Approved | $6.66B | 17 |
| IMCR | Immunocore | DermatologyInfectious Disease+2 | 8 | Approved | $1.44B | 12 |
| IMNM | Immunome | Oncology Rare | 6 | NDA Submitted | $2.03B | 9 |
| INAB | IN8bio | ImmunologyOncology | 3 | Phase 1 | $8.9M | 4 |
| INBX | Inhibrx Biosciences | Oncology | 3 | NDA Submitted | $1.10B | 6 |
| INSM | Insmed | CardiovascularImmunology+3 Rare | 7 | Approved | $26.7B | 15 |
| IVVD | Invivyd | Infectious Disease | 1 | Approved | $152M | 5 |
| IONS | Ionis Pharmaceuticals | CardiovascularHematology+5 Rare | 2 | Approved | $4.49B | 29 |
| JBIO | Jade Biosciences | ImmunologyRenal Rare | 1 | Phase 2 | $1.07B | 4 |
| JANX | Janux Therapeutics | Oncology | 4 | Phase 1 | $655M | 4 |
| KAPA | Kairos Pharma | Oncology | 1 | Phase 2 | $1.9M | 12 |
| KZIA | Kazia Therapeutics | NeurologyOncology Rare | 2 | Phase 2 | $60.7M | 13 |
| KROS | Keros Therapeutics | NeurologyOncology Rare | 1 | Phase 3 | $222M | 5 |
| KPRX | Kiora Pharmaceuticals | Ophthalmology Rare | 1 | Phase 3 | $4.1M | 4 |
| KURA | Kura Oncology | MetabolicOncology | 8 | Approved | $688M | 13 |
| KYMR | Kymera Therapeutics | DermatologyImmunology+1 Rare | 2 | Phase 2 | $10.4B | 5 |
| KYTX | Kyverna Therapeutics | ImmunologyNeurology+1 Rare | 1 | NDA Submitted | $297M | 6 |
| LBRX | LB Pharmaceuticals | Neurology | 1 | Phase 3 | $1.30B | 3 |
| LEGN | Legend Biotech | Oncology Rare | 16 | Approved | $3.12B | 17 |
| LXEO | Lexeo Therapeutics | CardiovascularNeurology Rare | 2 | Phase 2 | $236M | 12 |
| LCTX | Lineage Cell Therapeutics | MetabolicNeurology+1 Rare | 2 | Phase 2 | $207M | 13 |
| LQDA | Liquidia | CardiovascularImmunology+1 Rare | 4 | Approved | $5.11B | 9 |
| MAIA | MAIA Biotechnology | Oncology | 1 | Phase 3 | $77.2M | 8 |
| MRKR | Marker Therapeutics | Oncology | 4 | Phase 1 | $14.0M | 5 |
| MAZE | Maze Therapeutics | MetabolicRenal Rare | 1 | Phase 2 | $1.80B | 4 |
| MBX | MBX Biosciences | Metabolic Rare | 1 | Phase 3 | $2.64B | 4 |
| MDNAF | Medicenna Therapeutics | Oncology | 2 | Phase 2 | $14.8M | 10 |
| MGTX | MeiraGTx | ImmunologyMetabolic+2 Rare | 3 | Phase 3 | $827M | 16 |
| MESO | Mesoblast | CardiovascularGI/Hepatology+2 Rare | 2 | Approved | $1.54B | 5 |
| INKT | MiNK Therapeutics | ImmunologyOncology+1 Rare | 2 | Phase 2 | $47.7M | 8 |
| GLUE | Monte Rosa Therapeutics | CardiovascularDermatology+3 Rare | 4 | Phase 2 | $775M | 7 |
| NKTR | Nektar Therapeutics | DermatologyImmunology+2 | 1 | Phase 3 | $1.23B | 11 |
| NKTX | Nkarta | ImmunologyNeurology+1 Rare | 8 | Phase 1 | $89.6M | 8 |
| NBP | NovaBridge Biosciences | OncologyOphthalmology | 4 | Phase 2 | $95.4M | 7 |
| NRXP | NRX Pharmaceuticals | Neurology Rare | 1 | Approved | $109M | 11 |
| NRIX | Nurix Therapeutics | ImmunologyNeurology+1 | 8 | Phase 3 | $1.56B | 13 |
| NVCT | Nuvectis Pharma | HematologyOncology+1 Rare | 6 | Phase 3 | $660M | 9 |
| OCGN | Ocugen | Infectious DiseaseOphthalmology Rare | 4 | Phase 3 | $257M | 12 |
| OLMA | Olema Pharmaceuticals | Oncology | 2 | Phase 3 | $633M | 3 |
| OMER | Omeros | HematologyNeurology+2 Rare | 2 | Approved | $1.04B | 6 |
| ONCY | Oncolytics Biotech | Oncology | 1 | Phase 2 | $51.7M | 4 |
| IRD | Opus Genetics | Ophthalmology Rare | 2 | Approved | $391M | 12 |
| ORIC | Oric Pharmaceuticals | Oncology | 2 | Phase 3 | $831M | 5 |
| OVID | Ovid Therapeutics | Neurology Rare | 1 | Phase 2 | $419M | 4 |
| PALI | Palisade Bio | Immunology | 1 | Phase 2 | $181M | 3 |
| KTTA | Pasithea Therapeutics | NeurologyOncology Rare | 2 | Phase 1 | $16.0M | 4 |
| CATX | Perspective Therapeutics | Oncology | 4 | Phase 1 | $104M | 5 |
| PHIO | Phio Pharmaceuticals | Oncology | 3 | Phase 1 | $8.6M | 4 |
| DTIL | Precision Biosciences | Infectious DiseaseMetabolic+1 Rare | 4 | Phase 1 | $197M | 5 |
| PRLD | Prelude Therapeutics | HematologyOncology Rare | 3 | Phase 1 | $266M | 3 |
| PRME | Prime Medicine | GI/HepatologyRespiratory Rare | 2 | Phase 1 | $699M | 3 |
| PCSA | Processa Pharmaceuticals | GI/HepatologyImmunology+2 Rare | 3 | Phase 2 | $4.8M | 7 |
| PMN | ProMIS Neurosciences | Neurology Rare | 1 | Phase 1 | $28.9M | 9 |
| PRQR | ProQR Therapeutics | MetabolicNeurology Rare | 2 | Phase 1 | $163M | 7 |
| PTGX | Protagonist Therapeutics | DermatologyHematology+2 Rare | 2 | Approved | $8.14B | 12 |
| RXRX | Recursion Pharmaceuticals | Oncology | 2 | Phase 2 | $1.69B | 6 |
| RLAY | Relay Therapeutics | DermatologyOncology Rare | 1 | Approved | $3.64B | 4 |
| RVMD | Revolution Medicines | Oncology | 2 | Approved | $35.2B | 11 |
| RYTM | Rhythm Pharmaceuticals | Metabolic Rare | 2 | Approved | $8.08B | 14 |
| RCKT | Rocket Pharmaceuticals | CardiovascularImmunology Rare | 2 | Approved | $236M | 4 |
| SGMT | Sagimet Biosciences | DermatologyMetabolic | 1 | Phase 3 | $709M | 3 |
| SANA | Sana Biotechnology | MetabolicOncology | 1 | Phase 1 | $563M | 4 |
| SRPT | Sarepta Therapeutics | NeurologyRespiratory Rare | 5 | Approved | $1.58B | 11 |
| SCYX | Scynexis | Infectious DiseaseRenal Rare | 3 | Approved | $28.4M | 5 |
| SEPN | Septerna | ImmunologyMetabolic+1 Rare | 2 | Phase 1 | $1.90B | 5 |
| SION | Sionna Therapeutics | Respiratory Rare | 4 | Phase 2 | $139M | 5 |
| SLDB | Solid Biosciences | CardiovascularNeurology Rare | 2 | Phase 3 | $695M | 6 |
| STOK | Stoke Therapeutics | Neurology Rare | 1 | Phase 3 | $1.73B | 2 |
| GPCR | Structure Therapeutics | MetabolicRespiratory Rare | 2 | Phase 3 | $3.90B | 5 |
| STRO | Sutro Biopharma | Oncology | 2 | Phase 1 | $148M | 3 |
| SNDX | Syndax Pharmaceuticals | ImmunologyOncology Rare | 1 | Approved | $822M | 7 |
| TNGX | Tango Therapeutics | Oncology | 5 | Phase 1 | $3.75B | 5 |
| TECX | Tectonic Therapeutic | Cardiovascular Rare | 2 | Phase 2 | $401M | 4 |
| TLX | Telix Pharmaceuticals | Oncology | 7 | Approved | $3.01B | 25 |
| TGTX | Tg Therapeutics | Neurology Rare | 2 | Approved | $9.48B | 6 |
| HURA | TuHURA Biosciences | Oncology | 3 | Phase 3 | $92.1M | 4 |
| TYRA | Tyra Biosciences | MetabolicOncology Rare | 2 | Phase 2 | $1.35B | 5 |
| UNCY | Unicycive Therapeutics | Renal | 1 | NDA Submitted | $108M | 2 |
| QURE | uniQure | HematologyMetabolic+1 Rare | 2 | Approved | $1.46B | 4 |
| VNDA | Vanda Pharmaceuticals | CardiovascularDermatology+6 Rare | 3 | Approved | $230M | 27 |
| PCVX | Vaxcyte | Infectious Disease | 2 | Phase 3 | $9.40B | 7 |
| VKTX | Viking Therapeutics | MetabolicNeurology Rare | 3 | Phase 3 | $3.43B | 9 |
| VIR | Vir Biotechnology | Infectious DiseaseOncology Rare | 4 | Phase 3 | $1.58B | 6 |
| VRDN | Viridian Therapeutics | ImmunologyOphthalmology | 2 | Approved | $3.41B | 7 |
| VYGR | Voyager Therapeutics | MetabolicNeurology Rare | 2 | Phase 1 | $94.6M | 9 |
| VTVT | vTv Therapeutics | HematologyMetabolic+1 Rare | 1 | Phase 3 | $69.4M | 9 |
| WVE | Wave Life Sciences | MetabolicNeurology+1 Rare | 3 | Phase 2 | $560M | 5 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 21 | Approved | $2.59B | 28 |
| XENE | Xenon Pharmaceuticals | Neurology Rare | 4 | NDA Submitted | $3.81B | 9 |
| ZBIO | Zenas BioPharma | DermatologyImmunology+2 Rare | 3 | NDA Submitted | $1.88B | 11 |
| ZURA | Zura Bio | DermatologyImmunology Rare | 1 | Phase 2 | $99.7M | 4 |
| ZYME | Zymeworks | OncologyRespiratory | 5 | Approved | $1.78B | 12 |
No companies match.